A. Oaknin, L. Gladieff, Jerónimo Martínez, Guillermo Villacampa, M. Takekuma, U. D. Giorgi, K. Lindemann, L. Woelber, N. Colombo, L. Duska, Alexandra Leary, Ana Godoy-Ortiz, S. Nishio, A. Angelergues, María Jesús Rubio, L. Fariñas-Madrid, S. Yamaguchi, Domenica Lorusso, V. D’hondt, Leslie M Randall
{"title":"427 BEATcc(ENGOT-CX10/GEICO 68-C/JGOG1084/GGOG-3030),这是一项关于一线阿特珠单抗联合贝伐单抗和铂类化疗治疗转移性(IVB期)、顽固性或复发性宫颈癌的随机3期试验","authors":"A. Oaknin, L. Gladieff, Jerónimo Martínez, Guillermo Villacampa, M. Takekuma, U. D. Giorgi, K. Lindemann, L. Woelber, N. Colombo, L. Duska, Alexandra Leary, Ana Godoy-Ortiz, S. Nishio, A. Angelergues, María Jesús Rubio, L. Fariñas-Madrid, S. Yamaguchi, Domenica Lorusso, V. D’hondt, Leslie M Randall","doi":"10.1136/ijgc-2024-esgo.11","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"427 BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent or recurrent cervical cancer\",\"authors\":\"A. Oaknin, L. Gladieff, Jerónimo Martínez, Guillermo Villacampa, M. Takekuma, U. D. Giorgi, K. Lindemann, L. Woelber, N. Colombo, L. Duska, Alexandra Leary, Ana Godoy-Ortiz, S. Nishio, A. Angelergues, María Jesús Rubio, L. Fariñas-Madrid, S. Yamaguchi, Domenica Lorusso, V. D’hondt, Leslie M Randall\",\"doi\":\"10.1136/ijgc-2024-esgo.11\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"30 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.11\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
427 BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent or recurrent cervical cancer